Having trouble accessing articles? Reset your cache.

Biotech industry urges CFIUS to scale back regulations

Biopharma companies and investors are calling on the Treasury Department to scale back plans to restrict foreign investment in U.S. companies that collect genetic information.

About 60 comments to Treasury on the regulations, which implement the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), were recorded on Regulations.gov as of Oct. 18, a day after the deadline for comments.

Under the regulations, companies collecting or maintaining

Read the full 663 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE